Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

被引：0
|
作者：
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
机构：
[1] McGill Univ, Royal Victoria Hosp, Hlth Ctr, Montreal, PQ, Canada
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[5] Renown Reg Med Ctr, Ctr Hope, Reno, NE USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Reading, MA USA
[7] Univ Montreal, Montreal, PQ, Canada
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] ImmunoGen Inc, Waltham, MA USA
[10] Kadmon Rsrch Inst, Wilmington, MA USA
[11] ImmunoGen, Waltham, MA USA
[12] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[13] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6004
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer
    Chelariu-Raicu, Anca
    Stur, Elaine
    Ivan, Cristina
    Coleman, Robert L.
    Sood, Anil K.
    Wen Yunfei
    CANCER RESEARCH, 2020, 80 (16)
  • [22] Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1
    Ponte, Jose F.
    Ab, Olga
    Lanieri, Leanne
    Lee, Jenny
    Coccia, Jennifer
    Bartle, Laura M.
    Themeles, Marian
    Zhou, Yinghui
    Pinkas, Jan
    Ruiz-Soto, Rodrigo
    NEOPLASIA, 2016, 18 (12): : 775 - 784
  • [23] MIRVETUXIMAB SORAVTANSINE AND BEVACIZUMAB IN FOLATE RECEPTOR aLPHAPOSITIVE OVARIAN CANCER: EFFICACY IN PATIENTS WITH AND WITHOUT PRIOR BEVACIZUMAB
    O'Malley, David
    Oaknin, Ana
    Matulonis, Ursula
    Mantia-Smaldone, Gina
    Lim, Peter
    Castro, Cesar M.
    Provencher, Diane
    Memarzadeh, Sanaz
    Method, Michael
    Wang, Jiuzhou
    Esteves, Brooke
    Moore, Kathleen
    Gilbert, Lucy
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A7 - A8
  • [24] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
    Moore, Kathleen N.
    Martin, Lainie P.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Kirby, Maurice William
    Zhou, Yinghui
    Michenzie, Mary F.
    Ponte, Joseph
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
    Moore, Kathleen N.
    Martin, Lainie P.
    O'Malley, David M.
    Matulonis, Ursula A.
    Konner, Jason A.
    Perez, Raymond P.
    Bauer, Todd M.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1112 - +
  • [26] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
    Moore, Kathleen N.
    Borghaei, Hossein
    O'Malley, David M.
    Jeong, Woondong
    Seward, Shelly M.
    Bauer, Todd M.
    Perez, Raymond P.
    Matulonis, Ursula A.
    Running, Kelli L.
    Zhang, Xiaoyan
    Ponte, Jose F.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    CANCER, 2017, 123 (16) : 3080 - 3087
  • [27] Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer
    Zhu, Fengying
    Tu, Ya-Ping
    Sloss, Callum
    Wang, Yuemei
    BIOANALYSIS, 2024, 16 (21-22) : 1101 - 1113
  • [28] Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
    Borghaei, Hossein
    O'Malley, David M.
    Seward, Shelly Marie
    Bauer, Todd Michael
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Michenzie, Mary F.
    Kirby, Maurice William
    Chandorkar, Gurudatt
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
    Bogani, Giorgio
    Coleman, Robert L.
    Vergote, Ignace
    van Gorp, Toon
    Ray-Coquard, Isabelle
    Oaknin, Ana
    Matulonis, Ursula
    O'Malley, David
    Raspagliesi, Francesco
    Scambia, Giovanni
    Monk, Bradley J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 469 - 477
  • [30] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
    Matulonis, Ursula A.
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Romeo, Marga
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Method, Michael W.
    Esteves, Brooke
    Coleman, Robert L.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345